Press Releases

22/09/2022 OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results

08/09/2022 OSE Immunotherapeutics Announces Participation In Upcoming Investor Conferences

05/09/2022 OSE Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer after Failure to Immune Checkpoint Inhibitors at ESMO Congress 2022

13/07/2022 OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer

23/06/2022 OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting

16/06/2022 OSE Immunotherapeutics Announces Collaboration with Microsoft

09/06/2022 OSE Immunotherapeutics Appoints its International Scientific Advisory Board

07/06/2022 Four Poster Presentations at 2022 ASCO Annual Meeting

23/05/2022 OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi® in Immuno-Oncology at ASCO 2022

18/05/2022 OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression - A Study Sponsored and Conducted by Veloxis Pharmaceuticals, Inc., the Company’s Partner in Transplantation

11/05/2022 OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ in London and Boston

03/05/2022 Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

02/05/2022 OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy

04/04/2022 OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy At American Association for Cancer Research Annual (AACR) Meeting 2022

30/03/2022 OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities

21/03/2022 OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment

16/03/2022 OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine

09/03/2022 Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at AACR Annual Meeting 2022 New Orleans, April 8 – 13

1 2 3 4 5 6 7 8 9 10 11 12